Effectiveness and acceptability of medical abortion provided through telemedicine

Obstet Gynecol. 2011 Aug;118(2 Pt 1):296-303. doi: 10.1097/AOG.0b013e318224d110.

Abstract

Objective: To estimate the effectiveness and acceptability of telemedicine provision of early medical abortion compared with provision with a face-to-face physician visit at a Planned Parenthood affiliate in Iowa.

Methods: Between November 2008 and October 2009, we conducted a prospective cohort study of women obtaining medical abortion by telemedicine or face-to-face physician visits. We collected clinical data, and women completed a self-administered questionnaire at follow-up. We also compared the prevalence of reportable adverse events between the two service delivery models among all patients seen between July 2008 and October 2009.

Results: Of 578 enrolled participants, follow-up data were obtained for 223 telemedicine patients and 226 face-to-face patients. The proportion with a successful abortion was 99% for telemedicine patients (95% confidence interval [CI] 96-100%) and 97% for face-to-face patients (95% CI 94-99%). Ninety-one percent of all participants were very satisfied with their abortion, although in multivariable analysis, telemedicine patients had a higher odds of saying they would recommend the service to a friend compared with face-to-face patients (odds ratio, 1.72; 95% CI 1.26-2.34). Twenty-five percent of telemedicine patients said they would have preferred being in the same room with the doctor. Younger age, less education, and nulliparity were significantly associated with preferring face-to-face communication. There was no significant difference in the prevalence of adverse events reported during the study period among telemedicine patients (n = 1,172) (1.3%; 95% CI 0.8-2.1%) compared with face-to-face patients (n = 2,384) (1.3%; 95% CI 0.9-1.8%) (82% power to detect difference of 1.3%).

Conclusion: Provision of medical abortion through telemedicine is effective and acceptability is high among women who choose this model.

Level of evidence: II.

MeSH terms

  • Abortifacient Agents, Nonsteroidal / administration & dosage
  • Abortifacient Agents, Steroidal / administration & dosage
  • Abortion, Induced* / adverse effects
  • Administration, Buccal
  • Administration, Oral
  • Adolescent
  • Adult
  • Cohort Studies
  • Female
  • Humans
  • Middle Aged
  • Mifepristone / administration & dosage
  • Misoprostol / administration & dosage
  • Patient Satisfaction*
  • Pregnancy
  • Telemedicine*
  • Voluntary Health Agencies
  • Young Adult

Substances

  • Abortifacient Agents, Nonsteroidal
  • Abortifacient Agents, Steroidal
  • Misoprostol
  • Mifepristone